<SEC-DOCUMENT>0001193125-16-690463.txt : 20160825
<SEC-HEADER>0001193125-16-690463.hdr.sgml : 20160825
<ACCEPTANCE-DATETIME>20160825060755
ACCESSION NUMBER:		0001193125-16-690463
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160825
FILED AS OF DATE:		20160825
DATE AS OF CHANGE:		20160825

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prima BioMed Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		161850337

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d248311d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13A-16</FONT> OR
<FONT STYLE="white-space:nowrap">15D-16</FONT> UNDER THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated August 25, 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">001-35428</FONT> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>RIMA</SMALL> B<SMALL>IO</SMALL>M<SMALL>ED</SMALL> L<SMALL>TD</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of Registrant&#146;s Name) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by
check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;</FONT><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;</FONT><FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (1):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by
Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;
&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): Not applicable. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: August 25, 2016 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>Prima BioMed Ltd</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:75.45pt; font-size:8pt; font-family:Times New Roman"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">EUROPEAN PATENT GRANTS FOR IMP731 ANTIBODY</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d248311dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g248311ex991logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Code: ASX: PRR; NASDAQ: PBMD) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">25&nbsp;August 2016 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EUROPEAN PATENT GRANTS FOR IMP731 ANTIBODY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (&#147;Prima&#148;, the &#147;Company&#148;) announces the granting of patent number 2142210
entitled &#147;Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease&#148; by the European Patent Office. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent relates to Prima&#146;s IMP731 antibody (originally developed by Immutep SAS). The granted claims provide protection for specific sequences of
anti-LAG-3 antibodies and their use in depleting LAG-3<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cells by complement dependent cytotoxicity (CDC) and antibody-dependent cell cytotoxicity (ADCC). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rights for the development of the IMP731 antibody were granted in December 2010 to GSK, which has commenced first-in-human clinical trials of the proprietary
antibody (GSK2831781) derived from IMP731. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About IMP731 and GSK2831781 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMP731 and GSK2831781 are designed to specifically deplete potentially pathogenic, recently activated, LAG-3 expressing T cells which are enriched at the
disease site in T-cell driven immuno-inflammatory disorders and should spare other T-cells which may be necessary for other functions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of
the 2010 agreement between Immutep and GSK, GSK has responsibility for all development and associated costs for GSK2831781. Prima BioMed may receive payments and potential milestones totalling up to &pound;64&nbsp;million and is eligible for
single-digit, tiered royalties if all objectives are achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Phase 1, first-in-human clinical study of GSK2831781 for the treatment of autoimmune
diseases has commenced and further information may be obtained at <U>https://clinicaltrials.gov/ct2/show/NCT02195349</U>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Prima BioMed </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is a globally active biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment
of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima&#146;s current lead product is IMP321, based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune
response. IMP321, which is a soluble LAG-3Ig fusion protein, is an APC activator boosting T cell responses. IMP321 is currently in a Phase II clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov
identifier <U>NCT 02614833</U>) and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier <U>NCT 02676869</U>). A number of additional LAG-3 products including antibodies for immune response
modulation in autoimmunity and cancer are being developed by large pharmaceutical partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is listed on the Australian Securities Exchange,
and on the NASDAQ in the US. For further information please visit <U>www.primabiomed.com.au</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information please contact: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prima BioMed Ltd: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australia Investor/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr Matthew Gregorowski, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (2)&nbsp;8234 0100;
<U>mgregorowski@citadelmagnus.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew Beck, The Trout Group LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (646)&nbsp;378-2933;
mbeck@troutgroup.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prima BioMed Ltd</B>, Level 12, 95 Pitt Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 8315 7003 Fax: +61 2 8569 1880 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.primabiomed.com.au &nbsp;&nbsp;&nbsp;&nbsp;ABN: 90 009 237 889 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g248311ex991logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g248311ex991logo.jpg
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M P,# P,# P,# P,# P,# P,# __  !$( '0"Q@,!$0 "$0$#$0'_Q #?  $
M  8# 0$              0(#! 4'!@@)"@L! 0 " P$! 0$!           !
M P($!08'" H)$  ! @4"! ,$!0@&" 4#!0 ! @, $00%!A('(3$("4%1$V%Q
M(A2!D3(5"J&QP=%"4B,6\'(S%S<9X?%BDK(D)1B"8S1WN*+2XD-31%BH$0 "
M 0("!@4&!PH*"0('     0(1 P0%(3$2$P8'05%A<0B!D=$B,A2AL<%"4F(7
M\.%RTB,S4R0T%8*2HD-C<W06& GQ1%2T)35UMC>#D[+"XK-%)AG_V@ , P$
M A$#$0 _ /OW,4S]HDA&($ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0
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M\UQ:X"OM%WI"ZNG<#:PE#M/64M6VIFHIG4H?IW4J0XE*@1&.[[2:FW(K @!
M" (Q*U, Q,_:!",0( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $
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M#<[IFR+"=K<HHGK3EEBQ/"-RL/M"<OR>R5C:7+-49S45CBJ>G=3\PFC9;6L
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MC]PW"PVHK<L30M:C\G37FYV=JL2A "0XM:I K,VH'VC#E_IG^7QC79(@! "
M(Q*U, Q,_:!",0( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ (
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M3E-Y1QN5XEIJJW,-M4[=ENC[#L+8>IWIWRAAEVQ[Z[3UR5Z%!*,\QM+R@?\
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MS%.S*;I6;HE7I=5J.N5\V+WQQ)U=-D^S.ZEBJ&R4K178%D6F29_$7FJ-3*0
M/WC' Q/"V;X=5E:GYF?1L!SAY7YI+9P>>8*KZY+TFOG:.MMSCK5SH;M:WFQ-
M35?9ZZF6!.1.BHIZ=1D1(\Y><<F66YG:7K6I4[F>IL\4<+XR*E@L=8Q4?I6Y
MI)/J>G7TE9MZG>6E+-0R\".;2TJF?8 HJ'N,:LXRMU=VW-474=*U)8E;6&E"
MGX<:E5N6H@^!E]9 X^TSC0>,A%5_+/O+MG%VZJ[&[.-.M>@R[;@0F1EQY3$^
M1,Q[(V\%C%=3:K&G65.Q=ORVK#W$%K5QI-_@ZO*7K)#DI2E[)@<C^J-QW8_.
MEH(GB,+AJ1NW)2E71LS5"\3/4"!XB4^7Y9\ 8QN)3T0DB[$7<8XTLJ[%]CCZ
M"[$E/A/CI!/T<?;.-9V+J:WCB^HY&W=;:Q]Z57[.]=?XM*?"9!KX0%#AX>R2
M3_IC>LX3$R7J*U0PEEMW$>M8Q&$2ZG7TF1"1\/ $#C+2GC[#PC6E*/L[$*KL
M.7'#6[,OR=4T^ALNFB"I!"4)4A0*5)3(@GA/G[(U[]N%^FUHIU&U;O3BG&X]
MY&FJ71W&4:=6"9'[03,3)!),B9&?.4+=N,%H.5B[5B[IE")D&5DA23R"@M!!
M(*%B0U(*2/RSBF.'G"6W&[=U]9ISC>CHWLW#J=&N[5T%X6VU- EIHKEJ+BFF
MW%GXM,M3B%$"7EQC<C<Q,52-ZXEWE<9VDWO+5FY7Z4$_D,DRPRG3)'$(!G,I
M),R/V"D>$;-O'8ZWJNS\YIW\'E^(]K#6%W0CZ#+TU95TJD_*5EQHB% ZJ&Z7
M*C7J!^T%L52%)4/ B1$66\TS.T]J.(NU[S2Q>2Y'BK6[NX+"]5=W&OQ&S+#N
MSNEC@:=L>Y&<VM24EML4V47B2?B!$R[5N%0FGB#,&.KAN*,ZA*BO2T+K9X7'
M\M^!\:_^(Y;AL1:;KLS@ME/K5*:3;ULZONJ2W>FBFWUSTH2D#TJBNI:IL<92
ME44;A(EYDQV;/'7$-CV+IYC%<D.4V+;=S(L$NY27Q,YS0==G5G320G>&Z/I1
MI$JVSV.LU <]1=H>:I<92CLVN9?$L();4'H[3S^,\-O*6^MI9=&VGT1;27=I
M-DV3N,]4-KT.OY%BUW4$E*C=<7HY+U2Y_)JI_B$N$;-GFMQ)A9[R6YDM5&FU
M\9Y#&^%'E9B/V:UB+%^OM0DD^U:5J-FVWNB=0*4D5N-;;5NDI&H6^Y4Y4)<?
M@:N+G/V#A'5M\XL^DM-O#>:7I//W_"5P.I4M8C,5_#A\L3E]'W5-U6D)35[7
M8#5%)2DK:N%^HRN9$SH+CB43GRE&W9YR8I3V<5:LUKIHGZ3E8KP8Y3?@\3@<
M]5F,M*MW:.<>R5$M)L2U]U*O4I#=\V7:5.?J+LV6":9<BE%7;EDS]_*.TN;N
M7[O:E&*EY?E9Y'%^#S-K;<<%G&%O2Z%32_A-G6ON@;>/I N&VN:T1.G_ --6
MV>X"?[?#52N<#PY&<;V&YKY-<_.)GF<5X3>-[#]7%X1KR^DYK0]R;9&J2!46
M/.Z%W]I#UGIG"F9D.#=;J,_='17,_ANM)-U/+XSPV\?X6Y*W;W5U+YT:T?QG
M+:?N ]/KZTI<O-]I"?M!_&KJN7#]]AEQ(EXQOX?F+PS?N*U&34GVGG\5R#YC
MX:#N;F#BNQU.3T/6YT\5YTHSYBD492%QM%WHP9\)!;M($\#S\HZ?]\N'::+B
M\YP;W)[F+;=%AJON^^<^M/4WL;=VTFEW0P\N*)'IN7)+#@D>!*'PV4@CSBZ'
M%&27:2A<6QWG+O<N^.<%+=XG+[TYK2W&+I3X?C.8T^[>W-6 JDSW#Z@&6D(O
M]K25$C@GXZI,ISC?MYUE%YJ$+BVWJTG*O<-<2V:J678K;_!?H,RSFV/57Q4V
M18RZCG-%\MRS+V%-44F-KWC#?I(>?[YH2RK/K7YW+\4G^"_095B^T%0F;5QM
M;W&4VKA2.&?D V\H&(=^QK5R%.]>DHE8QD5^4PU^$NIK3\1?)KFU<4*:6/$H
M>;5+SY$\8RC=M3DHQN0VF:\_>8:[%RG<5/F3S"2H<.1!Y^4A&QN)_3@:\\5.
MVO7LW$0-0LRTHEYZ@9_H@[%SHE%EEK$6[L=J3=MUU26DCZ[DOLB?NX?\7*(W
M%WKB6[RST35>YDP=7XEL^X__ )&,=W>[#';[B5=0M,N"#/\ V@)?EC)6+\M5
M [L%[32?>2?-+_<1_OC]<9+#7EKI0C?VM6U&O>!4/$_91X^*?_N/*,Z6=5)5
M\IDKD_T<Z%0/D?VFE)\.(/Z1$.$7[*8WCZ827>1^91^\G^G_ (HC==C&\74_
MN\A:_-O^+7T2_28G=QZF:V_C^FC_ .W(JMU:S/U&P@<)34E,Y^4U<8B48KH9
M9;G.;>[>\IU1<:><JA^?$%L ^;B)^7[T8TC]&1;3$?HV0]=7]$JBG:?T68.Y
MV_ 2*JB@ D3F9?95$TE/4U#\+I)5Q]'K?!\9+\[[!_NJ_5#=W/TMKS??)VY_
M17\9%.3?&0<&HS)3^T2=4^,QQ]W*+TZ*E&S'>/Z/\I$6D-H<6XGU"I20F2].
ME*0$CX  "DF0GYB7D(.DM:="=XWHHH][1=!P@2"?Z<(;,.J1.W]:/G7I(>LY
M/@@2C&B^BQMQ^FO,R'K.C]@?TE[?;!-1T[+&W#IFO,Q\PY^Z/#P/C*)WL.J7
MW>0C;M_3_DL>NYPX#ZCPY0WL>ID.<:Z)JG<QZ[GDGZE0WL>ID.:6J:\S(^NY
MY)^I4-['JD8[SZ\?,R'S"O%)G[!P^B?E&+O)?-D9J<7\]>9CYE7[BO\ =@KJ
M;ILR)4[=?6N*G<Q\R?!,C[4J/YHSVGU,QG>LK0KBKW,"IX<2@'Q!!!\_%0E&
M+G1THPKT6JIQ?E2^!Z2!JI"<T'W3)^@3,S$.4I+9CZLNMZO*9*XVZ>K_ !D2
M_.@\OR@C\AB-WB/TMK[O*3*<EJBOXR(_-'Q*4_I]L0[>)Z+EI_=WF,;LJ>M#
M^4B(JO:E7L D3[ 20(*.)3K*=MQZEK)=Z*57&FCZ2)OF%'D@#QXJ!^K28MVO
MJLJ]YB47*MU!D&TD2G.8'YR.435_1D9QNJ<=I5\B;^%$!6O$@>A,$@$S\S*8
MXF%?JR(WT5H]9O\ !9<%]R7]G+W_ .N,=Y'I3^[R$QO2>NW+SH?,*2#K3(\P
M DGAX<I^,9*L],%H[2U.4M46N]DOS7'@!](4/KF.$9*$^G42XW5I<:1ZZA-3
MJY% \CJ2?R SB9QHJQ:*5B+%S1"Y"OW=H4\XDCBWQ\"#Y<N?&*HN4OG11+NJ
MWHFXMO51D#4.C_\ 3*CYI0HCCRESB6G].!8MN2K%*G>B*GW$C44H2@?:*CID
MG][4HA&E/C%/O%JWIO3BEYB8>NZ)/S''KCF6/6KA<<AQRWDZM(K[W;*,J2GF
MK_F*QOAQ^B(>89;%5E>CYT;4,NS7$NF782_B7T[$9/9ZJT3UG KIU![+V%+G
MW]N]M=:E-?V@JLZQIE38(F-:%W36)I,^4:MS.\JMZ=]"G:T=3#\)<98E[-O*
M,<Y/^CG^*=>LL[DW13A*5F_]2&V@=0%'Y6U7&HO=4YH/Q!ANU4]87E2' )!)
MCSUWCWA:VZ*XZI]9[S*^1G-S-VHX3A_';3U55/C2.O%[[VW0?:BM%!FV99*L
M%8;%CVYR?TW2G]@/7&FHT)*O!2M*3'.N<R>&K2;E)L^DY=X.>?.9TE'*9V+=
M*MW'3S=QI+(^_MTWV\NHQK:;=_)%I2?2-2QCM@8=6.2?5J+E6.ME7^TW''Q'
M-OAVV_R>TUWH]_EG@0YGXJ*>8XS!X275.,F_@:.IN7_B"L^=<<1@_37BM"RX
MM?I'+\TNMPJ/1*CH6IJT4%&V70F1*1J2#P$X\GB^=]B#:PUNVVGTU])]?RG_
M "X\4]BYGW$5B%II-JVDG3IUUH97:OO3=2F;8)U.YY=-O-IV/[F=L\ S#&<?
MHZ;(DL5MRRG?+;K;:O9NU<Y7+JW*1JQY94.-AMM*A4(03-,P<,MYR8_&X',<
M9*U92P>'M7$E%Z7/$6K+KIZKC?>6<5^!KEWD6?\ "^0X7/[URYGF9XO#7IMP
MI:C8RS&8V,EH^==P\+>GHD?3^8_0T_:/\NR$8@2!YB< 2SD9!/ >SA$;R494
M2K$,IJ0?*9\ARC9<MN&S%I2:\Q3NE"6\3=46SC*G!(M)]NI(/#F.)]L51]XM
MZ=M,S5VZ_9E.+[BCZ!0L#T_ ?8924B9X_%,1;"[>GHE)%%[W=S_6;4[U[Z=.
MCJ\A7<9)&H>H%:3*2=4CQ\SP_-$223VYM2BG6G7V".'@WM)SC#I576G44FVG
M5A2'TZT$?9=;24GZ"3%%Q8#$*D[.CM2-J,X0=</O8/O9QF[;>87?3_UC#L2N
MB2E25?>.-V>N4=4]7Q55$XJ1!C4GEN3S6S+#P?;LHWL/G?$N#=<OS'%8>'3&
M$YJKZ]$D==\OZ%^DK.7:AS).G;;>J>=4I:JNCL;%I=6XL?$O_HZ[?I5,\_..
M3>X.X=Q5=NS"K[#V.!YN\R\J48X/.,=M0:I63:JM5:MZ.LT3>NTQT47E+B6-
MIZK'5.(4V7<?RO(Z()U<-2&_O!P ^V./=Y<<--?FH>8^A9;XJ>>F"DI7\RWJ
M70Z>;4:.R'LE=.EQ?GCV<;KXNUH/IM-UUDO3#*@1(?\ 5;:[4J!'_F<?&.)C
M>4F28UJ5AJTDM76>YP/C-YF6VI9E9L8IK5M-QIYJFM+WV-L7+;CN-[^9.P\
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M4MW<7"CC>:FM6DYTL!B[=U8J^L-*W'2XI*K[-1E6-"?3D3P/$)6XD)$I<0%
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MU>U#3GR6/;-6_BI*5(Q6^5JT@@@"=5DGIK4GV) /E%<N<V/<:*#3?8>BP?\
ME^<LDMJ]F682CK<6EI75KT5U&JKSWD.NVXDF@SK";$/_ -NU[>6(R'L5<S7.
M ?3'+N<U\YDGLQD>LP?@5Y)V9)RCBO._2:^N?=3Z^+JF;N_-92S"A*UXUBUJ
M4C49R2:6VH)(\"22(XN+YDY_B)*4-N%$>NP'@VY$X)-7LOEB:ZMJ;CL]FC74
MU[<^X7UQWE*FZSJ8W-80J<A17=B@'$:2!\G3(4 1YQJOF#Q')4WD]*ZV=O#^
M%7D)A9J5O(8.2:>F;=6NO1I79J9I/)>HCJ$RQ'HY1OSN]>OVGFJG/<@12KU&
M7IE%+7,(*1Y:91RY\39Y?=9XF7G9])P7*CEG@M%KAO*8KLPUM>?U=)IVY5MQ
MN50JIN-XO-Q>6)*?K[W=ZUQ7F"NIK73*-:]CLUOT_6W5=IZC"<#\%V$_W=E>
M78/579M0AM=6I::&)--3J4'%M-N+'[;@+J_9\3I6HQR[M[.&_P!I;\K.A#)\
MHPOJVL)@W%/Z$?05&VFVQ_#0AOCQ"$)3XS\ !SB;6)NUI<VNVIUGB5!4P+C:
MG^"E0G' D\B3J*AS)\U'B28OO7+;BM;TFI?OXO%I1SG%XB=J+_)JRM3Z=O2M
M%-1*M/PKT@ RFK2.)ER)\)Q0H862]9:2[#W';7ZK"%R/]/K^&I8\9"?'@0>,
MO>/IC55C"PE50J6RPTJ;5Z&&E731/1W:CMOT]@?W!=?' ?X$[-^(_P#[:;)1
MZW(KMAY)G:5II+!6*Z-?Z[AU3Y3XQS%M9?\ :%R^4<':C_Q_,:_67[@S/0^Y
MTEWH_0 ,?MB?M'\\Y",0( 0 @! " $ ( 0 @! " $ ( I^FD$JC.*3K4PG%2
MH^E%JM"M14G4GE]@_:D/VCS,O?%E(K442OWX+9BM'<6*Z-"TJ2[Z3Z3S#S*7
M>!/(I<2M)$_"*I1P5]*-R"\Q-EW,(]J%W%/37VOB.+W+ <*O@6S></Q2YL/Z
MDNMUUBM[X="A)06'&% S$:.)R+(;J_+6XM^1G<P?%>>89KW+$8ZW)=*FU\IH
MK*>BGI4R/UE738?;IQ=1)2W:*V?<SFKC-7J6NHH%ZU'F>9CBWN#N&[^K#QKW
M'J\-S@YEY5&F#S[$6(I:%.;:\QIFM[8?1_==:48%6V3U"I(_E_)L@MY;U&?P
MEYZI3-,^9G')O\L>'[\:N$:/L/>X+Q-\]L/&.^S.%RTDJ/9K5+4_*:XO_:)Z
M=JDDV#)]SK HJ,T-7RWW-"4R,DRN-M4L@*X\YF.0^3O#]RK@E!]>CT'KL%XS
M.:6 :6+C8QBU;.Q2G;6IK&Y=G#%=*E63>S)*4G[ O&/6NMTSF9*-$_0!21_5
MGYF.1BN3&%;KAYKX3V6#\;?&32W^6V=HU-?^T'N;1!:L5W=PN[ +4I--=[+=
M[0\N1.E2G:=RM9 4.?/G'&QG)?%PA7#W*L]/E_C8R"Y/9S+*;JQ"]MIJCETT
M7Q&H;IVO.K"VK6JFMV 7EE*M#:Z'+4T[KB3,A8:K:1HI0=($B9S,>=?*+B&U
M<K&7PGM,-XP>7.8I6,9A[^"@M.W1NKZM%3@MRZ#.K&R!:GMIJNY):'Q*LEZL
MUR60#+X6D5:'5&0Y2C2O\JN)/IO3VGL,L\27)C$I;[&7*]-4U\9JF];';T8R
MZIB^;3[A6]3.KU"K%KE5-I+<RL>I0MU23*7/E'*O<)Y[AJV)69R<'2M'I9Z[
M#<U^!\P2OX#-<.L)/3!2G':2Z*Z=9PQRQ7^B4HW#'LAMPTD$W"Q7:CE.4@0_
M2(D3*./B,@SFRMMV)T3ZF=RUQGP_C%N\'F6&G>?1M+5YPTL) ;\4B2OB2DI/
M$R6E:@I) \Q%$</FEA4]WGYCJX?%1Q=':Q>&?=->DRC!U )0 HI XI,QQ\E"
M8,8._CXMN[8DE7J9E/$-3=A8%8B:_G(R5)=JTE\VEU*P9 Z2"H3"53\-"%$*
M<3QXD#@(GWJ-SU';V9]9KXG#8R-O?7, [%JOMU32^'I,NT]KU$SX:1X$SX^W
MA YYE:?D?I_1%]OV2F?M,RS)TI!]H_* /TQ=;]M%<M1DFERF/!0!/N'A^6-H
MYU_Y69>F>#<DI!D./A[9_7%\/9*(ZC,LNHT"9/&9^O\ 3&8FMJ#CV%=#R=02
MDR*C+]/Z(@T]P_NJ7S=4IM.F85(GCP/EYQ="Y&,:/63N&5Q5+(!F/J$9[V/:
M1N'U$CE4N0XCGY >!AOH]HW#ZBU??);$U?M_H\(JN24W5%D(."HRV4\DH6DD
MS)5,_3%3U&=*Z#%/N H6D+ ,N?'Z>0G&N4^[_=I,$^M 0D@DS!G[]0BJYK1T
M,''=P:[3%O.I23P/+V#P$5HW*59BG'4J5J$^0X0+S%U"53U R$N7'^GA&$C9
ML:F8QT:R0KB.$O/D)SC$O,:M6E)5SE+\I A=]DW$8YQT(4%D$A6K@)3_ &8Y
ME_VD91]HQ3Y64F1D"9@?3Q_/&N;UG4S&NK!;6./%)_ISB3>,83I*5>4_T0(>
MM&-J!^4D_61%\/9-RQ[)8/+T-ZAX\![#*<XU'K+2P6H."0F%3F2>1$I<AXP1
MG#66-004B95P,N'OEY^V,72IOV6S&%!F9'A[29_IB2^3>T^\M'')@I$^$C/^
MGOB4]EU,K;>T8VJ69)1\4YA4_K'Z8RWBZR^KZS'/%)09@SF./M\^<8.C=3IV
M9-VEI98/$ZOMJ,_ ^[W\($W&]DQ]03-/$\H(LL-TUO[F6BEZ2D&?Q G@?*?Z
MHDOJ^LLC-:S(RTSG,_1^B(>HR@WM:V4E.E&H<SX^(X<?&,:(NJ^MF)>=U.\9
MS5/EX2@2F]I%D1.8/(QET&U5[!26D)29>,O+]$.@RM:_+\ACG5 )(,_M*_.(
MQ-N71W%H5N2_M7"/W3IE[O.423;_ #B[RC,)3QXJ*IS$N4OH@= I*,S,>42"
MV/,^\_G@"F[_ &:O=&<3*&OR%E^RG^HG\T1+63+VD2RDTI/B5E?T<_KC%>T;
MEKI786\;QB0,5SUA"*R5K+1S[;G]/$14=!ZRW<^RGWG\PC*.LU[^I%&,S7$
M3)C">HLMZR5;H1J2025)'E[?UQ66%C&1>M2.W'3W_@%U\_\ L3LW_P#+/9*/
M49'_ ,DSO^Q6/]]PY\?YC?\ D+E[_P!?S+_M_,S]  Q^UY^T?SPD(Q @! "
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M+3B&$%'&9=8Q$EKN*3AM>11HJ:CA=Z[9V8TK2EXYNI8+C(32Q>K'54*UD$2
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M_P"Z62TT0BCTN%YM\T<-+:6:3;[6VOB.'5_0CT_5RU!O';[;T*204T.2W!*
M9\TBH54+2?8"!*-#%<"Y-B)J2HJ([V'Y^\U,)+9>,WBZ]?H.&77MU;-52"+5
M>,XM#@"@DHN]/6)' @<*JC=F)GV1ISY>91.$H57K*AZ+#^)3F5:BMY?C.*UI
MK6NKRFNJWMFXV[-5OW.RJF5PTIJ[=:*A'M"BVTRLS_K1P;G*'+'[-]G?POBG
MXFBUO<)\*^^<,NO;'ORB/NG=>WJDDR^\,;?"ISX:E4U84_3ICEXCDU@I>M"]
MZR/0X3Q4S3_XGE]VY*NAPDDDNW2C6=^[:.]-,K5:,MP2_)$R/7^]+6\.$]+?
MJ,/-"9X>$HX5_E+C[4Z8:3E'O1[# >*KAG8_6,!B87>MRJD^O0S5UPZ >J*G
M!13XGCM=R.NGRNW\O$ 5:4.3/]:448GE5G37Y.+;[UZ3U."\4W#%R2][NJ*[
M83^2)PBZ=$G5+1":]IZRJ"0J:Z&^6&LU2(^PW3UZ5'GPU"?E'#N<MN*<$_4P
M\[D9?66CX3U6$\1W+;%_G<PMVIKKA<5?*XT-7WOIKZA+$?4N&SN<MM()!-+9
MGJX#AQDFWNU,P)> BI\"\5I5>$GYUZ3TF'YY\N;]-C-++KHU2UOR&G[KAN<6
MMS1=,,RZW2'$5F.7A@CWZZ,>4<O$\/9S9B][8FCV-GC_ (-Q--UF&&DW]9'%
MWF:MDEM^BN#*R#\+]!6,D2\_583*7MCA7,IS&<FE:EHUZ#O8'B/(;]=UB\.]
M7SX^DXY5.M-S2M:&R")AQ0;EP'/5I YQH7<+B++I<A)/N9Z*Q.QB56Q>L27]
M9#\8L%U+:TE*5)*E"20E0))\) <3%6Q/Z,O,S;C;G-[,55EHH'B">)!D"9'Z
MCQ$66WL5<DU5=3+Y6YX-*YB(N,9:%H]!B%G02% A0XE,IJD3P^$3/&-2]B;,
M=;?F?H+[:=[3:3:[F4'1Z@4$?%)!.D>'PCP,N,X)[2JM3+76+I)2KW/T&)6%
M$*2 20#, 'AP\?"'Q&*>^]6"=5V-?&8\SU)1)6H) *9$\9GR!\XMC8N7%6"J
MN]%T/R>B6AEC4F:R!S"9&? A0G,&?B(EX>\M:^%>DVHRBTJ,L.?$?LGB?+@>
M$1N;G5\*-FQ%RG1-+1TM+XS'/\7"?#SAN;G5\*])>XI:Y0_C1])9N_$A0'.?
M*(=FXM:.A87Y-):>[28QX+"BK2> Y\/#GS,52:BJLVXVKBI)KU2S62LC@2>/
ME[/+R@I1>HB4XPTR="V*TS/'\\&])="<7!26IEHM0"5>$Y3,O:.?G$-J*J]1
ME&[#;2TU[BPJ3/U% S!")$3_ -!\(F+VO9-J,92U)^8Q3@FKAY#ZY<8SV6M:
M-J-BXH;35%WHM'$K)^$&7L,O >V,=I5ITE;:BZ/66QX&1X&))7K:BW>(TJ]T
M0S=LPEL:BFEQ 9"2KXIGAQ\S N49)U>HLW2=4P>!ERX<?UQ!;MQZRC R33U%
MNOAJ(Y\?TQ)DM:+1Q:B-)$N/]/$Q+5#*=(KJ*7A$&$6I-4ZR4J$B)^SQ\C!>
MTC?M?(6\;QB"(KFFWH(JDZ/60'.,'%I%L82;5$6K@(4LGD>7U@_FBDW2V<Y
M>T_HB8M)Z2B\FTJ%*1\HSVD:^S+J(1)!,.1^C],8R+[&MEH]]OZ!&!LE* .W
M'3W_ (!=?/\ [$[-_P#RSV2CU&1_\DSO^Q6/]]PY\>YC?^0N7O\ U_,O^W\S
M/T #'[7G[1_/"0C$" $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @!
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MNYLQ2H62I<-)U \Y> _T0+8SVY*--9263(223Q\(DNW*[/,4"H@R*2/?P_7
MAQV="*2CP4?>8+63'VEWE@M>I9$I2"3S]WLC.0O])","FSJ\I0/C[_UP6LZ=
MKI[B2-XQ$#*,[<=$]9!:](\R03+^@C&6IG0M7K*714M%KU^$N/G/PEY1J$%N
MYX<_'D9>4"&D]92E[3]9@8["$6FDR(Y'Z/TQC(OL:V6CWV_H$8&R4H [<=/?
M^ 77S_[$[-__ "SV2CU&1_\ ),[_ +%8_P!]PY\>YC?^0N7O_7\R_P"W\S/T
M #'[7G[1_/"0C$" $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! "
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MU\-QYQK@U3#9MF,$NK$7?QC3=\Z".CG(75O7+IUVT6XM&A3E+9$V]2DRE_\
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:^??+_P"[MNFW[Q[GB-_NOK^Y[_:_H]H__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
